Biogenvs.Gilead Sciences
BIIB vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 5.5× larger than Biogen by market cap; year to date, Biogen leads (+23.9% vs +19.6%).
Side by side
| BIIB | GILD | |
|---|---|---|
| Market cap | $31B | $170B |
| Price | $220.77 | $148.77 |
| Today | +1.2% | +1.4% |
| Return YTD | +23.9% | +19.6% |
| Return 1Y | +56.6% | +27.9% |
| P/E | 37.2 | — |
| P/S | 3.1 | 5.6 |
| P/B | 1.6 | 14.4 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →More BIIB & GILD comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and GILD sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →